UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Mar

    31

    Employee Spotlight: Judith Thompson’s Journey to Making a Larger Impact through Addressing Health Disparities for People Living with Severe Diseases

    Mar

    18

    Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

    Mar

    17

    Exploring the future of dermatology at AAD 2023

    Mar

    16

    You Speak, We Listen: How Community Voices Drive Our Work in HS

    Mar

    16

    UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

    Mar

    15

    Building a Community of Trust in Epilepsy & Rare Syndromes